Editor
Introduction
It has been suggested that inflammation is involved in the pathogenesis of Alzheimer's disease (AD) [1] . Specifically, the accumulation of microglia around senile plaques and elevated levels of inflammatory cytokines, chemokines, proteases, and reactive oxygen species have been observed in the brains of AD patients. In and around the senile plaques and neurofibrillary tangles, microglial cells are activated, and the number of reactive astrocytes is increased. Collectively, these data have led to the hypothesis that brain inflammation is a cause of neuronal injury in AD.
Prostaglandins (PGs) are chemical mediators and potent inducers of inflammation. Cyclooxygenases (COXs) catalyze the conversion of free arachidonic acid to the endoperoxide intermediate PGG2, which is then reduced by peroxidase activity to PGH2. PGH2 is metabolized rapidly, resulting in different end products depending on the relative abundance of synthases in different cell types.
Examples of these end products include PGI2, thromboxane A2, PGD2, PGE2, and PGF2 alpha.
PGE2 is also catalytically converted from PGH2 by prostaglandin E synthase (PGES). It has been reported that levels of PGE2 are increased in the cerebrospinal fluid (CSF) of AD [2] , and the highest levels are observed in the very early stages of AD. These levels then decline with progressive cognitive impairment [3] . In vitro experiments have revealed that PGE2 release is enhanced by amyloid beta (Abeta) [4] , a major constituent of senile plaques found in AD brains. Furthermore, Abeta induced COX-2 activity may subsequently catalyze the production of PGE2 [4] .
The four receptor subtypes of PGE2 are E prostanoid (EP) receptors1-4. Deletion of the EP2 receptor in aged amyloid precursor protein (APP) Swe-PS1ΔE9 mice, which were used as a transgenic mouse model of AD, results in lower levels of Abeta peptides and less accumulation of amyloid deposits [5] .
Conversely, the metabolism of Abeta might be influenced by PGE2. Therefore, PGE2 may play a key role in the early stages of AD pathogenesis, especially in Abeta-related events.
PGES is a membrane-associated protein involved in eicosanoid and glutathione metabolism. There are three types of PGES: cPGES, mPGES-1 and mPGES-2. Cytosolic glutathione (GSH)-dependent prostaglandin (PG) E2 synthase (cPGES) is a terminal enzyme of COX-mediated PGE2 biosynthetic pathway. Functional coupling between COX-1 and cPGES was reported to be important for the synthesis of PGE2 [6] . Microsomal PGES-1 (mPGES-1) is a perinuclear protein that is markedly induced by proinflammatory stimuli, and is functionally coupled with COX-2.
Microsomal PGES-2 (mPGES-2), another PGES, is a Golgi membrane-associated protein. The proteolytic removal of its N-terminal hydrophobic domain leads to the formation of a mature cytosolic enzyme [7, 8] . In addition, over-expression of full-length mPGES-2 was found to be spontaneously converted to the N-terminal truncated form. This truncated version of the enzyme is similar in size to the deletion mutant mPGES-2, which lacks 87 amino acids at the N-terminal [8] .
The cleavage of mPGES-2 regulates its enzymatic activities.
Beta-site APP-cleaving enzyme 1 (BACE-1), also known as beta-amyloid-converting enzyme 1, has been identified as a membrane-bound aspartic protease, chiefly located in the Golgi apparatus.
Amyloid precursor protein (APP) is first cleaved by BACE-1 and subsequently by gamma-secretase to generate beta-amyloid. Inhibitors of BACE-1 are proposed therapeutics for AD. Recent reports indicate that novel substrates are cleaved by BACE-1 [9, 10, 11] . Proteolytic cleavage can control the fate of enzymes, and thus BACE-1 might contribute to the regulation of enzymes.
It has been suggested that BACE-1 is one of the stress-responsive proteins. In this study, we investigated the function of BACE-1 in Abeta-induced inflammation, and revealed that mPGES-2 might be cleaved by and colocalized with BACE-1. Astrocyte cultures. Primary astrocyte cultures were obtained from postnatal day 1 (P1) rat cortex.
Materials and methods

Reagents
Briefly, dissociated cells were seeded into 75-cm 2 tissue culture flasks and incubated for 20-24 days in Eagle's minimum essential medium (EMEM) supplemented with 10% FBS and 50 µg/ml kanamycin at 37ºC in a 5% CO 2 /95% air humidified incubator. Flasks were shaken at 400 rpm (10 min, 37ºC) and then at 220 rpm (15 hr, 37ºC 
PGE2 and Abeta enzyme-linked immunosorbent assay (ELISA).
After cultures were treated in neurobasal medium containing 2% B27 supplement for 24 h at 37 °C, debris was removed by centrifugation, and the media were then applied to ELISA plates. The culture media were analyzed for prostaglandin production using a monoclonal PGE2 enzyme-linked immunosorbent assay Statistical Analysis. Statistically significant differences between groups were determined by an analysis of variance followed by a Dunnett or Newman-Keuls post-hoc analysis. The level of statistical significance was taken at p < 0.05.
Results
Abeta induces the production of PGE2
To investigate Abeta-induced inflammation, we measured extracellular PGE2 levels induced by Abeta, using an ELISA. Administration of Abeta 1-42 for 48 h significantly increased PGE2 levels in the media of neuronal culture (Fig. 1A) . Simultaneous administration of BACE-1 inhibitor IV (200 nM) significantly suppressed Abeta 1-42-induced PGE2 up-regulation (5 M, 48 h). These results suggest BACE-1 is involved in the production of PGE2 induced by Abeta. In contrast, exposure of neuronal cells to lipopolysaccharide (LPS) also significantly increased PGE2. Secreted levels of PGE2 were more prominent than PGE2 levels resulting from Abeta stimulation, and BACE-1 inhibitor IV did not suppress LPS-induced PGE2 up-regulation (Fig. S1 ).
Previously, we demonstrated that exposure of Abeta 1-42 to neuronal cultures increased BACE-1 protein levels [12] . As the Abeta peptide might form a cross-linked complex directly with COX-2,
we investigated the effect of indomethacin, a COX inhibitor, upon Abeta-induced BACE-1 up-regulation (Fig. 1B) . Administration of Abeta 1-42 for 48 h significantly increased BACE-1 expression levels. Simultaneous administration of indomethacin (10 M) significantly suppressed Abeta 1-42-induced BACE-1 up-regulation (5 M, 48 h) in a concentration dependent manner.
Ibuprofen also attenuated the BACE-1 up-regulation induced by Abeta (data not shown). These results suggest COX activation may be involved in the increase of BACE-1 levels.
Abeta enhances the protein levels of BACE-1, COX-2 and PGE2 synthase
We next investigated the cell type responsible for the production of PGE2. cPGES, mPGES-1, and mPGES-2 are responsible for the synthesis of PGE2. Therefore, the protein levels of these enzymes were analyzed by western blotting (Fig. 2A ).
Exposure to Abeta increased the protein level of mPGES-2 significantly in pure neuron and astrocytic cultures. On the other hand, Abeta did not affect cPGES levels in any cell culture. In all cultures, mPGES-1 was not detected. These data suggest that mPGES-2 may be an inducible enzyme that is responsive to Abeta.
COX-2 activity can also be induced by various stimuli or stress. It has been reported that expression of COX correlates with levels of Abeta. Therefore, we evaluated the expression level of COX-2 using pure neuronal, astrocyte, and microglia cultured cells. As shown in Figure 2A , COX-2 levels were enhanced by Abeta treatment in all cell cultures.
Although BACE-1 was not detectable in the microglia culture, BACE-1 expression was determined to be enhanced in the pure neuronal culture and in the astrocyte culture.
N-terminal 20-residue peptide of mPGES-2 was cleaved by BACE-1
It has been shown that 87-residues of the N-terminus of mPGES-2 can be cleaved in the cytoplasm, resulting in an active form of mPEGS-2. This fragmentation leads to the release of mPGES-2 from the Golgi membrane and allows mPGES-2 to migrate to other intracellular organs. In order to clarify the involvement of the cleavage of the N-terminal sequence by BACE-1, we prepared a 20-residue peptide including the 87 th amino acid sequence of mPGES-2 (Fig. 2B) . After the in vitro reaction of this synthetic peptide (20AA) with recombinant BACE-1, the peptide wacs separated by reverse HPLC using a C18 column.
HPLC analysis revealed a single peak when the 20AA peptide was administered alone. Following the reaction of 20AA with BACE-1, three peaks were found. Two of the peaks might represent the cleaved peptides, while the other is the original peak. These results suggest thatBACE-1 can cleave mPGES-2.
PGE2-induced neuronal death
Simultaneous treatment with BACE-1 inhibitor IV, which reduced Abeta-induced neuronal death, also reduced Abeta-induced PGE2 production. We therefore investigated whether PGE2 is toxic to neurons using MTT assay. As a result, administration of synthetic PGE2 induced neuronal death in a concentration dependent manner (Fig. 3A) . From these data, we concluded that Abeta administration leads to the augmentation of PGE2 mediated via BACE-1, which in turn induces, at least in part, neuronal death.
Extracellular Abeta secretion was increased by PGE2-related inflammation
Previously, it was indicated that PGE2 caused Abeta secretion [13] . We also confirmed that Abeta 1-40 or 1-42 levels were augmented by PGE2 treatment. Synthetic PGE2 treatment significantly increased the Abeta 1-40 and 1-42 levels in a concentration-dependent manner (Fig. 3B, C) .
Colocalization of mPGES-2 and BACE-1 or COX-2 was induced by Abeta
To clarify whether mPGES-2 colocalizes with BACE-1 or COX-2, mixed culture cells were immunostained and analyzed by photomicrographs. mPGES-2 colocalized with BACE-1 in cells after exposure to Abeta (Fig. 4A ).
While COX-2 did not colocalize with mPGES-2 in a resting state (Fig. 4B) , administration of Abeta led to the colocalization of mPGES-2 and COX-2. Simultaneous administration of the BACE-1 inhibitor attenuated the Abeta-induced colocalization of mPGES-2 and COX-2. Exposure to Abeta induced the assemblies of mPGES-2, BACE-1 and COX-2 in the perinuclear region (Fig. 4B ).
COX-2 is mainly located in the nuclear membrane. Lamin-A, a nuclear membrane marker, colocalized with mPGES-2 after exposure to Abeta (Fig. 4C) . Simultaneous administration of the BACE-1 inhibitor attenuated this phenomenon.
These data suggest that Abeta induces the association of BACE-1 and mPGES-2, which causes the migration of mPGES-2 to the perinuclear region where COX-2 is located.
Discussion
BACE-1 is an aspartic protease, and cleavage of APP has been investigated for the elucidation of AD pathogenesis. In addition to APP, novel BACE-1 substrates have recently been identified [9, 10, 11] .
BACE-1 might be activated by various stress stimuli, and it might therefore cleave stress-reactive peptides.
mPGES-2 is synthesized in the Golgi membrane, and it then undergoes a proteolytic event where its N-terminal hydrophobic domain is removed. This truncated enzyme is subsequently released into the cytoplasm. Abeta stimulation induced the translocation of mPGE2 to perinuclear region where BACE-1 also assembles. Therefore, it is possible that BACE-1 cleaves mPGES-2 in the perinuclear region. Further supporting this hypothesis is the fact that mPGES-2 possesses one hydrophobic region, and it is therefore possible that its enzyme structure is similar to that of APP, another known BACE-1 substrate.
The 20-amino acid synthetic mPGES-2 peptide was determined by EMBL Nucleotide Sequence Database (Accession number AK024100) to contain the N-terminal 87 th amino acid sequence of PGE2. The full-length protein of mPGES-2 is spontaneously converted to an N-terminal truncated form, which is similar in size to the reported deletion mutant of mPGES-2 that lacks the N-terminal 87 th amino acid sequence [8] . We hypothesized that since either mature or truncated mPGES-2 has been reported to exhibit bioactivity, that cleavage product of PGE2 mediated by BACE-1 would be bioactive, we therefore prepared this peptide.
Full length mPGES-2 is associated with the Golgi membrane, and it is dispersed in the cytoplasm after removal of the N-terminal region [8] . However, our data suggest that Abeta-stimulated cells exhibit assemblies of mPGES-2 and BACE-1 around the nucleus. IL-1beta-treated fibroblasts show overlapping expression of COX-2 and mPGES-2 primarily in the perinuclear region [14] . mPGES-2 is constitutively synthesized and is not regulated by IL-1beta. Some stimuli might cause the translocation of mPGES-2 without up-regulation in protein synthesis.
It has been reported that both COX-1 and COX-2 mediate mPGES-2-promoted PGE2 production, with COX-2 being slightly preferred [8] . In our data, Abeta induced the translocation of COX-2 from the nucleus to the perinuclear region, where mPGES-2 was also found. Treatment with a BACE-inhibitor attenuated this phenomenon, indicating the involvement of BACE-1 in this process.
BACE-1-induced cleavage of mPGES-2 would activate the enzyme promoting its translocation to the perinuclear region where it could couple with COX-2 and contribute to the production of PGE2.
In addition to the increases in the processing and translocation of mPGES-2, its protein levels were also augmented. The induction of PGE synthase mRNA levels by treatment of cells with Abeta has previously been reported [15] . However, the precise mechanism is not known, and it is not clear why mPGES-2 mRNA was up-regulated.
Previously we have reported that Abeta treatment induces increases in BACE-1 protein levels [12] .
This change may be due to increased BACE-1 transcription by Abeta [16] . BACE-1 may in turn cleave APP to produce more Abeta. In this study, we demonstrated that Abeta treatment leads to the production of PGE2, which up-regulates Abeta.
It has been reported that PGE2 stimulates the production of Abeta [13] . Specifically, PGE2 induces internalization of presenilin 1 (PS1), followed by the activation of gamma-secretase [17] . Abeta simultaneously up-regulates BACE-1, which causes ectodomain shedding of APP. APP is subsequently cleaved to produce Abeta, which propagates the vicious cycle of AD pathogenesis
Our data demonstrated that PGE2 treatment induced neurotoxicity. Abeta-induced PGE2 levels or PGE2-induced Abeta levels were not sufficient in quantity to result in neurotoxicity. Previously, we have shown that Abeta-induced neurotoxicity is attenuated by treatment with BACE-1 inhibitors [12] .
Neuroinflammation induced by PGE2 may aggravate AD pathogenesis in brains through this positive feedback cycle.
In conclusion, Abeta causes BACE-1 up-regulation, which cleaves mPGES-2, which is subsequently translocated to the perinuclear region where it synthesizes PGE2 collaboratively with COX-2. As a result, increased BACE-1 levels and neuroinflammation would lead to the up-regulation of Abeta. 
